The role of bisphosphonates in preventing fractures in osteoporotic patients
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Bisphosphonates have been the cornerstone of pharmacological fracture prevention in osteoporosis for over two decades, yet persistent questions about optimal agent selection, treatment duration, and the balance between skeletal benefits and rare but serious adverse effects continue to generate debate among clinicians and patients alike. This research compared the fracture-preventive efficacy, bone mineral density effects, safety profiles, and adherence patterns of four bisphosphonate agents against a calcium and vitamin D control group in a Czech two-centre cohort of postmenopausal women with established osteoporosis. A prospective parallel-group design enrolled 192 postmenopausal women aged 55 years and older with documented osteoporosis from two academic centres between July 2020 and April 2022. Participants were allocated to alendronate, risedronate, zoledronic acid, ibandronate, or calcium and vitamin D supplementation alone, with treatment selection guided by clinical factors and patient preference. Primary endpoints included new fracture incidence, change in lumbar spine bone mineral density at 24 months, and a composite fracture risk reduction estimate. Secondary outcomes encompassed medication adherence, gastrointestinal and musculoskeletal adverse events, and the incidence of rare complications including atypical femoral fractures and osteonecrosis of the jaw. At 24 months, zoledronic acid produced the greatest bone mineral density gain at the lumbar spine (mean +0.058 g/cm²) and the highest estimated vertebral fracture risk reduction at 62.1%, followed by alendronate at 47.3% and risedronate at 42.8%. Ibandronate showed more modest gains. The calcium and vitamin D control group experienced a mean bone mineral density decline of 0.008 g/cm² over the same period. Vertebral fractures constituted the most common fracture type at 38.4% of all events, followed by hip fractures at 24.7%. Twelve-month medication adherence was highest for zoledronic acid at 91.7%, reflecting its once-yearly intravenous dosing schedule, compared with 72.3% for weekly oral alendronate and 68.9% for weekly oral risedronate. Gastrointestinal adverse events were most frequent with alendronate at 18.4%, while musculoskeletal complaints were highest following zoledronic acid infusion at 16.8%. Rare adverse events were infrequent across all agents and did not differ significantly between groups. These findings support zoledronic acid as the most effective bisphosphonate for fracture prevention and bone density improvement when adherence is a concern, while oral agents remain acceptable alternatives for patients who prefer non-injectable treatment, provided that adherence is actively monitored and supported.
Fields of Study & Subjects
Bone health and osteoporosis research
Bone health and treatments
Menopause: Health Impacts and Treatments
Publication details
- Journal / source
- International Journal of Orthopaedics and Bone Disorders
- Volume
- 8
- Issue
- 1
- Pages
- 26–32
- Publication date
- 1 January 2026
- Language
- EN